Specifically, considering the current situation that there were no clinically viable drugs that directly target YAP in cancer, MLN4924, as a drug that could inhibit the activity of Skp2, might be a potential treatment agent for attenuating the proliferation of tumor cells in YAP-driven cancers. Here, SKP2 is linked to cancer.